Daily non-political popular news in brief.
St. Jude finds anti-leukemia drug increases patient fatigue
11-01-2007 · EurekAlert!The anti-leukemia drug dexamethasone contributes to a relentless fatigue and poor quality of sleep in children undergoing treatment for acute lymphoblastic leukemia, according to a new study from St. Jude Children's Research Hospital. The finding suggests that clinicians could improve the quality of life for these children by developing new methods of drug administration that reduce or eliminate these side effects.
Read more »
Keywords: jude, anti-leukemia, drug, patient, fatigue, anti, leukemia
« Previous | Next »
Similar news on "St. Jude finds anti-leukemia drug increases patient fatigue":
- St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
08-29-2007 · EurekAlert!
Results of a study by investigators at St. Jude Children’s Research Hospital provide strong evidence for why the targeted therapy drug, imatinib, or Gleevec™, which has revolutionized the treatment of chronic myelogenous leukemia, (CML) is often unable to prevent relapse of a particularly aggressive form of acute lymphoblastic leukemia (ALL).
Similar news · Read more »
- St. Jude shows gene test not needed if cancer drug given in low doses
06-19-2007 · EurekAlert!
Investigators at St. Jude Children's Research Hospital have shown that when the cancer drug irinotecan is given in low doses for multiple days, it eliminates the need to delay treatment to perform costly genetic testing that determines if the patient is at risk for serious treatment side effects, such as neutropenia.
Similar news · Read more »
- Leukemic cells find safe haven in bone marrow
03-22-2007 · EurekAlert!
The cancer drug asparaginase fails to help cure some children with acute lymphoblastic leukemia (ALL) because molecules released by certain cells in the bone marrow counteract the effect of that drug, according to investigators at St. Jude Children's Research Hospital.
Similar news · Read more »
- Complete response with oblimersen combination improves survival of CLL patients
12-09-2007 · EurekAlert!
Relapsed chronic lymphocytic leukemia (CLL) patients who had a complete response to combination therapy that included the drug oblimersen survived significantly longer than patients treated with chemotherapy alone, a team led by researchers at the University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.
Similar news · Read more »
- UCLA researchers discover biomarkers that predict lung cancer patient response to therapy
01-31-2008 · EurekAlert!
Researchers at UCLA's Jonsson Cancer Center have discovered biomarkers that predict which patients with advanced non-small cell lung cancer will respond to a combination treatment of the anti-inflammatory drug Celebrex and the growth factor receptor blocker Tarceva.
Similar news · Read more »
- Patient with rare disorder responds to cancer drug
02-13-2008 · EurekAlert!
A rare disorder caused by an excess of two types of immune cells -- the mast cell found in various tissues and its blood-based twin, the basophil -- has successfully been treated with a cancer drug, report scientists from NIAID.
Similar news · Read more »
- Study of leukemia survivors gives hints for better care
03-20-2007 · EurekAlert!
Results from the longest follow-up study ever done of childhood acute lymphoblastic leukemia (ALL) survivors show the importance of long-term monitoring of former patients to identify complications they are at risk for developing later in life and to modify current treatments to reduce those risks, according to investigators at St. Jude Children's Research Hospital.
Similar news · Read more »
- Mouse Tests Predict Drug Response In Relapsing Pancreatic Cancer Patients
10-12-2006 · ScienceDaily
By slicing up bits of patient tumors and grafting them into mice, Johns Hopkins Kimmel Cancer Center specialists have figured out how to accurately 'test drive' chemotherapy drugs to learn in advance which drug treatments offer each individual pancreatic cancer patient the best therapeutic journey.
Similar news · Read more »
- Targeting leukemic stem cells by Bcl-2 inhibition
11-17-2006 · EurekAlert!
Researchers at The University of Texas M. D. Anderson Cancer Center have found, in laboratory studies, that the experimental drug ABT-737 which has shown promise in some cancers, can destroy acute myeloid leukemia (AML) blast, progenitor and even stem cells that are often resistant to standard chemotherapy treatment.
Similar news · Read more »
- Novel drug preventing protein recycling shows potential for treating leukemia
04-19-2007 · EurekAlert!
Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found that a novel targeted therapy effectively treats acute leukemia in animal models by preventing cancer cells from being purged of damaged proteins.
Similar news · Read more »
